Hybridoma Sequencing with Reptor

Benefits of Hybridoma Sequencing by NGS

Next-generation sequencing (NGS) provides a comprehensive, high-throughput platform for sequencing hybridomas. The benefits of our process include:

• Sequence polyclonals – Deep sequencing each hybridoma reveals contaminating, minor clones that confound other sequencing methods.
• Protect your IP – Sequencing all hybridomas from your campaign reveals related sequences that can contribute to a stronger patent application.
• Never lose a hybridoma – Knowing the sequence of your valuable hybridomas gives you peace of mind in the event of hybridoma loss.
• Low sample requirements – The sensitivity of next-generation sequencing enables our process to start from as few as 10,000 cells.

Over 1000 hybridomas sequenced and counting!

Deliverables

• Dominant and minor sequences for each hybridoma

• Automated CDR detection on each sequence

• Clonality assessment for each hybridoma

Related Services

Digital Proteomics offers a suite of antibody sequencing and discovery services to complement your hybridoma workflow.

Proteomic mAb verification – We confirm by mass spectrometry that the produced antibody matches the hybridoma transcript sequences.

Reptor^TM bulk B-cell receptor sequencing– Complement your hybridoma campaign by sequencing related members of your hybridoma from remaining lymph nodes, spleen, or blood.

Valens^TM de novo protein sequencing – We determine the full-length sequence of your antibody directly from the protein, no hybridoma needed.

Did you know many hybridomas are not monoclonal? We can determine clonality of your hybridoma with our process. Read more about a recent assessment of 185 hybridomas in When monoclonal antibodies are not monospecific: Hybridomas frequently express additional functional variable regions.